Pataday Once Daily Relief®
olopatadine 0.2% · ophthalmic solution
Allergy
Approved uses
Allergic conjunctivitis, ocular itching
1 drop in each affected eye QD
Itch relief is present at onset of action and still holds 16 hours after a single drop.
OFF-LABELNot in the FDA label for this product
Ocular redness of seasonal allergic conjunctivitis
1 drop in each affected eye QD, the labeled regimen, used for 10 weeks in the trial
RCT · n=260
Randomized, double-masked, placebo-controlled environmental trial across a spring grass season (N=260): on high pollen days 14% of treated patients rated redness frequency above 2 versus 31% on placebo (P<0.003), against 21% versus 47% for itching (P<0.001). The OTC Use statement on this product claims itch relief only, so redness is an unlabeled endpoint here.
Contraindications
Do not use if you are sensitive to any ingredient in this product.
Ophthalmic solution, 0.5 mL bottle, 2.5 mL bottle, 2.5 mL two bottle carton, 2.5 mL three bottle carton, 0.2% (2 mg/mL)
Selective histamine H1 receptor antagonist that also stabilizes conjunctival mast cells, blunting the response to histamine already released while limiting further degranulation. In human conjunctival mast cells the molecule inhibits histamine, tryptase and prostaglandin D2 release, and its H1 affinity (Ki 31.6 nM) far exceeds its H2 and H3 affinity.
Warnings & Precautions
External use only: Topical ophthalmic use only, not for ingestion or injection.
Common Side Effects
- Challenge trial tolerability: No treatment-related adverse events among the 90 subjects in the conjunctival allergen challenge trial of this concentration.
- Seasonal use tolerability: In a 10 week environmental trial (N=260, including 28 subjects aged 11 to 17) no patient had a treatment-related serious adverse event and none discontinued for a treatment-related event.
Animal studies of toxic doses did not reveal evidence of teratogenicity. No human data is available. It is not known whether this drug is excreted in human milk
Labeled for ages 2 and older.